BIOGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 15.00K shares, a 0.00% change from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-06 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2025-02-12 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-14 | |
| 2019-12-31 | 15.00K shares 10-K · filed 2020-02-06 | |
| 2018-12-31 | 15.00K shares 10-K · filed 2019-02-06 | |
| 2017-12-31 | 14.00K shares 10-K · filed 2018-02-01 | |
| 2016-12-31 | 41.00K shares 10-K · filed 2017-02-02 | |
| 2015-12-31 | 114.00K shares 10-K · filed 2016-02-03 | |
| 2014-12-31 | 163.00K shares 10-K · filed 2015-02-04 | |
| 2013-12-31 | 523.00K shares 10-K · filed 2014-02-06 | |
| 2012-12-31 | 765.00K shares 10-K · filed 2013-02-05 | |
| 2011-12-31 | 5.24M shares 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |